Related Experiment Video
Updated: Oct 10, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Clinical perspective on clinical outcome assessments in neurosarcoidosis
Brandon P Moss1, Deborah M Miller2, Daniel A Culver3
1Sarcoidosis Center, Cleveland Clinic, Cleveland, OH 44195, United States; Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44195, United States.
Background:
There are no validated clinical outcome assessments (COAs) used in neurosarcoidosis.
Objective:
We surveyed clinicians who treat patients with neurosarcoidosis to determine: 1) current approaches to assessment of neurologic impairment, and 2) clinicians' needs regarding future COA development.
Methods:
Physician contacts from the Foundation for Sarcoidosis Research and Neurosarcoidosis Consortium Group were sent an online survey.
Results:
For 43/143 responders, COAs were used in a minority of settings. Apart from time for administration, the biggest barriers to implementation were lack of validated, disease-specific measures.
Conclusions:
Lack of validated, disease-specific measures is a barrier to monitoring neurological impairment in neurosarcoidosis.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Nursing Evaluation
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Nephrotic Syndrome II : Assessment and Medical Management
Psychosis: Goals of Pharmacotherapy
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

